Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery
Status:
Terminated
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to prospectively evaluate the response of recombinant
antithrombin (rAT) (ATRYN) in patients who are heparin resistant and are scheduled to undergo
cardiac surgery.
Phase:
Phase 4
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
rEVO Biologics
Treatments:
Antithrombin III Antithrombins Calcium heparin Heparin